Title : Fenretinide, Tocilizumab, and Reparixin Provide Multifaceted Disruption of Oral Squamous Cell Carcinoma Stem Cell Properties: Implications for Tertiary Chemoprevention.

Pub. Date : 2019 Dec

PMID : 31515297

1 Functional Relationships(s)
Compound Name
Protein Name
1 Notably, combination fenretinide-tocilizumab-reparixin treatment significantly suppressed IL-6 and IL-8 release, stem cell gene expression, and invasion in these diverse CSCE populations. Fenretinide C-X-C motif chemokine ligand 8 Homo sapiens